News + Resources
Keep up with the latest
Featured
Scribe Therapeutics Reports Preclinical Data Validating its CRISPR Genome Editing and Epigenome Modifying Technologies for Addressing Cardiometabolic Disease at American Heart Association (AHA) Scientific Sessions 2024
November 25, 2024
Scribe Therapeutics Reports Preclinical Data Validating its CRISPR Genome Editing and Epigenome Modifying Technologies for Addressing Cardiometabolic Disease at American Heart Association (AHA) Scientific Sessions 2024
November 25, 2024
CRISPR 2.0, the Next Generation
June 21, 2024
Aspen Ideas: Health
CRISPR 2.0, the Next Generation
June 21, 2024
All Stories
News
Sanofi’s NK cell toolbox grows with Scribe’s next-gen editor
September 27, 2022
BioCentury
Read Now
Press Release
Sanofi’s NK cell toolbox grows with Scribe’s next-gen editor
September 27, 2022
BioCentury
Read Now
News
Natural killers gain more attention with major Franco-US collab
September 27, 2022
The Pharma Letter
Read Now
Press Release
Natural killers gain more attention with major Franco-US collab
September 27, 2022
The Pharma Letter
Read Now
News
Sanofi partners with Scribe to gain gene editing tools for cell therapy work
September 27, 2022
Biopharma Dive
Read Now
Press Release
Sanofi partners with Scribe to gain gene editing tools for cell therapy work
September 27, 2022
Biopharma Dive
Read Now
News
Sanofi turns to a Jennifer Doudna gene editing upstart for next-gen NK cell alliance
September 27, 2022
Endpoints News
Read Now
Press Release
Sanofi turns to a Jennifer Doudna gene editing upstart for next-gen NK cell alliance
September 27, 2022
Endpoints News
Read Now
News
Sanofi, Scribe Launch Up-to-$1B CRISPR-Based Cancer NK Cell Therapy Collaboration
September 27, 2022
Genetic Engineering & Biotechnology News
Read Now
Press Release
Sanofi, Scribe Launch Up-to-$1B CRISPR-Based Cancer NK Cell Therapy Collaboration
September 27, 2022
Genetic Engineering & Biotechnology News
Read Now